Keen Vision Acquisition Stock Quote KVAC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

11.16

Bid

10.74

Ask

17.84

Volume

831

11.14 Day's Range 11.16

10.40 52 Week Range 11.16

Market Cap

216.125M

Previous Close

11.15

Open

11.14

Last Trade

100

11.16

Last Trade Time

Financial Volume

$ 9,266

VWAP

11.15

Average Volume (3m)

9,476

Shares Outstanding

19,366,000

Dividend Yield

PE Ratio

148.60

Earnings Per Share (EPS)

0.08

Revenue

Net Profit

1.46M

Sector

Blank Checks

Industry

Blank Checks

Headquarters

Road Town, Tortola, Vgb

Founded

Keen Vision Acquisition Corporation is listed in the Blank Checks sector of the NASDAQ with ticker KVAC. The last closing price for Keen Vision Acquisition was $11.15. Over the last year, Keen Vision Acquisition shares have traded in a share price range of $ 10.40 to $ 11.16.

Keen Vision Acquisition currently has 19,366,000 shares outstanding. The market capitalization of Keen Vision Acquisition is $215.93 million. Keen Vision Acquisition has a price to earnings ratio (PE ratio) of 148.60.

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping...

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of...

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular...

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology PR...

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating...

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation PR Newswire SUMMIT, N.J. and BOSTON, Sept...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.02	0.179533213645	11.14	11.16	11.09	2782	11.14003163	CS
4	0.06	0.540540540541	11.1	11.16	11.09	5225	11.11446031	CS
12	0.25	2.29147571036	10.91	11.16	10.91	9476	11.02315818	CS
26	0.47	4.3966323667	10.69	11.16	10.67	54016	10.76857369	CS
52	0.74	7.10172744722	10.42	11.16	10.4	54523	10.66386192	CS
156	0.96	9.41176470588	10.2	11.16	10.14	65065	10.50080437	CS
260	0.96	9.41176470588	10.2	11.16	10.14	65065	10.50080437	CS

KVAC - Frequently Asked Questions (FAQ)

What is the current Keen Vision Acquisition share price?

The current share price of Keen Vision Acquisition is $ 11.16

How many Keen Vision Acquisition shares are in issue?

Keen Vision Acquisition has 19,366,000 shares in issue

What is the market cap of Keen Vision Acquisition?

The market capitalisation of Keen Vision Acquisition is USD 215.93M

What is the 1 year trading range for Keen Vision Acquisition share price?

Keen Vision Acquisition has traded in the range of $ 10.40 to $ 11.16 during the past year

What is the PE ratio of Keen Vision Acquisition?

The price to earnings ratio of Keen Vision Acquisition is 148.6

What is the reporting currency for Keen Vision Acquisition?

Keen Vision Acquisition reports financial results in USD

What is the latest annual profit for Keen Vision Acquisition?

The latest annual profit of Keen Vision Acquisition is USD 1.46M

What is the registered address of Keen Vision Acquisition?

The registered address for Keen Vision Acquisition is RITTER HOUSE, WICKHAMS CAY II, PO BOX 3170, ROAD TOWN, TORTOLA, VG1110

Which industry sector does Keen Vision Acquisition operate in?

Keen Vision Acquisition operates in the BLANK CHECKS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
STAKSTAK Inc	$ 3.97 (156.13%)	173.35k
ORGOOrganogenesis Holdings Inc	$ 6.21 (102.28%)	58.69M
TRNRInteractive Strength Inc	$ 2.57 (67.97%)	192.48M
PMAXPowell Max Ltd	$ 0.511 (43.54%)	136.35M
ARBBARB IOT Group Ltd	$ 0.6635 (38.23%)	58.86M
NVNINVNI Group Ltd	$ 0.99 (-50.50%)	72.28M
SPGCSacks Parente Golf Inc	$ 0.2085 (-48.65%)	57.4M
ADGMAdagio Medical Holdings Inc	$ 0.8081 (-47.53%)	756.64k
PRAXPraxis Precision Medicines Inc	$ 38.60 (-40.64%)	3.17M
SAGSAG Holdings Ltd	$ 1.19 (-38.97%)	788.89k
NVDANVIDIA Corporation	$ 124.92 (3.97%)	389.48M
TRNRInteractive Strength Inc	$ 2.57 (67.97%)	193.57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 13.44 (7.78%)	154.46M
PMAXPowell Max Ltd	$ 0.511 (43.54%)	137.18M
LCIDLucid Group Inc	$ 2.22 (-0.45%)	136.17M

Rendering Error

Doc logic 5 minutes ago

sentiment_stocks,

Question is what would the volume have been if buying was permitted across all venues. Best wishes.

NWBO

TooFrank 5 minutes ago

This definitely could be the reason for NIO’s recent soft delivery numbers. NIO doesn’t reveal orders.

March 1, 2025
Wait times for both the ET7 and ES8 have been reduced to 2-3 weeks from 3-4 weeks previously, while the EC7 has been extended to 4-5 weeks from 3-4 weeks.

NIO

DimesForShares 5 minutes ago

KBLB will be facing a pivotal year. Pivoting so hard, it will make our heads swim!

Anybody else dizzy from all the pivoting KBLB has done?

KBLB

xodcode 6 minutes ago

Cut patient count or cost per patient in half still gives us $1,650 a share.

Let's estimate profitability as follows:

Year 1 - $80 million, $1.00 eps x 15 multiple = $15.00
Year 2 - $160 million, $2.00 eps x 20 multiple = $40.00
Year 3 - $400 million, $5.

AVXL

Livelikenotommorow 7 minutes ago

Just your typical OTC pump and dump we need them to get there head out of there rears and come up with some better pumps because what they been preaching is pretty bad .

CBDL

DimesForShares 8 minutes ago

Ah yes. A $10/share buyout offer coming 'soon!'

So so soon...

The KBLB way!

KBLB

againstallodds 8 minutes ago

JarHead unable to deliver the short term

Forget about any long term if he can’t deliver the short term

Stop that hype

He’s short of cash and can’t get that mill to run full scale

Next financials will be revealing and horrible

NBRI

janice shell 8 minutes ago

What can I say? He's ambitious. Evidently he was foolish enough to think hooking up with Trump was a good idea.

Livelikenotommorow 10 minutes ago

2025 will be a great year for the Hound !

SOUN

OMOLIVES 10 minutes ago

They will keep the obvious areas of Donetsk and Luhansk et al.....and will never let go of the Crimean Khanate. That has been the entire goal from the start. He will never go into to Poland because it is part of NATO. So there needs to be a pact with Ukraine via NATO without Ukraine becoming a me

ge11 10 minutes ago

https://www.washingtonpost.com/opinions/2025/03/01/trump-minerals-ukraine/

MasterBlastr 11 minutes ago

Former President dies . . . yes, and suddenly.

AMC

Boris the Spider 11 minutes ago

LG: "I contend that after the new Trump tax bill is signed into law, all the WMI recoveries will be returned to legacy WMI shareholders."

Large, not so sure it will take that long.
Note the 2 recent court filings by Judge Buckwald are under seal (as FDIC was granted).
I

COOP

Jetmek_03052 11 minutes ago

Keep on waiting.

What’s another decade or two?

LOL!

DBMM

arizona1 11 minutes ago

And bury this moron next to Ivana in NJ.

https://bsky.app/profile/franifio.bsky.social/post/3ljdu7r46tk2m

TightCoil 12 minutes ago

I didn't know what a shill was, then looked it up:
an accomplice of a hawker, gambler, or swindler who acts as an enthusiastic customer to entice or encourage others.

FNMA

nowwhat2 13 minutes ago

https://investorshub.advfn.com/uimage/uploads/2025/3/2/wthljXRP_~_1_6m_9pm_BOUNCE_NEEDED_DESPERATELY.jpg

https://investorshub.advfn.com/uimage/uploads/2025/3/2/otbmoXRP_~_2_6m_1pm_BOUNCE_TWEET_TRUMP.jpg

XRPUSD

janice shell 13 minutes ago

And you are forgetting it was the USSR that allowed Ukraine and others to become sovereign nations and now it is Putin who wants it back.

Not exactly. Ukraine was a Soviet Republic before the Soviet Union collapsed in 1991. It was Boris Yeltsin who agreed to set the Soviet Republics f

BDR10 14 minutes ago

Is it possible that he could just completely shock us tomorrow and actually say something with serious significance for this stock so someone on Wall Street will pay attention?

AVXL

janice shell 14 minutes ago

Good point.

TooFrank 14 minutes ago

Impossible. Unless the L60 is sold at a substantial loss.The CEO is delusional.

NIO

skitahoe 14 minutes ago

If brain shrinkage, which I believe we all experience after a certain age, were identified as a disease, we would be approved by now. Perhaps it should be, it no doubt diminishes all of us slightly, but to date it's not.

The question in the future may be, shouldn't we all be on it, w

AVXL

dukeb 17 minutes ago

it's not "the Ukraine," which is how Russia refers to the area because it refuses to acknowledge that UKRAINE is a sovereign nation.

And why in God’s great name are they restricting the Ukraine PUBLICLY?

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Keen Vision Acquisition Corporation (KVAC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Keen Vision Acquisition Corporation

Ask ADVFN Intelligence (AI)

KVAC Latest News

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

KVAC - Frequently Asked Questions (FAQ)

Movers

KVAC Financials

Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Keen Vision Acquisition Corporation (KVAC) Quote

Keen Vision Acquisition Corporation (KVAC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Keen Vision Acquisition Corporation

Ask ADVFN Intelligence (AI)

KVAC Latest News

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht

Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening

Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation

KVAC - Frequently Asked Questions (FAQ)

Movers

KVAC Financials

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free